Methods for treating circadian rhythm phase disturbances

• US 5,591,768 A
• Filed: 08/24/1993
• Issued: 01/07/1997
• Est. Priority Date: 12/04/1990
• Status: Expired due to Term

• Current Assignee: State of Oregon
• Original Assignee: Oregon State University (Oregon University System)
• Inventors: Sack, Robert L., Lewy, Alfred J.
• Primary Examiner(s): O SULLIVAN, PETER G
• Application Number:
  US08/110,878
• Time in Patent Office: 1,232 Days
• Field of Search: 514/415, 514/416, 514/418, 514/419, 548/491, 548/494, 548/495, 548/496
• US Class Current: 514/415
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/4045 Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for treating circadian rhythm phase disorders is described. The invention provides methods to specifically advance or delay the phase of certain circadian rhythms in humans. The disclosed methods relate to the administration of melatonin at times determined with relation to the time of dim light endogenous melatonin onset. Embodiments capable of alleviating the effects of jet lag, winter depression and shift-work sleep disturbance are provided.

Claims

1. A method for achieving a circadian rhythm phase-shifting effect in a human comprising the step of administering an amount of melatonin to the human over a treatment period, the amount of melatonin being sufficient to achieve a phase-shifting effect in the human, at an administration time prior to an individual human'"'"'s dim light melatonin onset time, wherein when the circadian rhythm phase-shifting effect is a phase advance, the administration time is from about CT 3 to about CT 22, and when the circadian rhythm phase-shifting effect is a phase delay, the administration time is from about CT 13 to about CT 6, and wherein the melatonin administration time on each day of melatonin administration can change during the treatment period, whereby the administration time remains at a constant time relative to the individual human'"'"'s dim light endogenous melatonin onset time or melatonin phase response curve.

2. The method of claim 1 wherein the phase-shifting effect is a phase advance and melatonin is administered to the human at about circadian time 7 to about circadian time 11.

3. The method of claim 1 wherein the phase-shifting effect is a phase advance and melatonin is administered to the human at about circadian time 7.5.

4. The method of claim 1 wherein the phase-shifting effect is a phase delay and melatonin is administered to the human at about circadian time 20 to about circadian time 2.

5. The method of claim 1 wherein the phase-shifting effect is a phase delay and melatonin is administered to the human at about circadian time 0.

6. The method of claim 1 comprising the additional step of determining the individual human'"'"'s dim light endogenous melatonin onset time by detecting an amount of melatonin or a physiological metabolite thereof in the human'"'"'s blood, urine or saliva over a period of time sufficient to detect the human'"'"'s dim light endogenous melatonin onset time.

7. The method of claim 1 comprising the additional step of estimating the human'"'"'s dim light endogenous melatonin onset time as being from about 1 to about 3 hours before the human'"'"'s normal sleep phase should begin.

8. The method of claim 1 comprising the additional step of estimating the human'"'"'s dim light endogenous melatonin onset time as being about 14 hours after the average time of the individual human'"'"'s initial daily bright light exposure time.

9. The method of claim 1 wherein the phase-shifting effect is the adjustment of circadian rhythms into synchrony with local time following transmeridional travel.

10. The method of claim 9 wherein the phase-shifting effect is a phase advance to alleviate jet lag caused by transmeridional travel to the east, and melatonin is administered to the human at about circadian time 7 to about circadian time 11.

11. The method of claim 9 wherein the phase-shifting effect is a phase advance to alleviate jet lag caused by transmeridional travel to the east, and melatonin is administered to the human at about circadian time 7.5.

12. The method of claim 9 wherein the phase-shifting effect is a phase delay to alleviate jet lag caused by transmeridional travel to the west, and melatonin is administered to the human at about circadian time 20 to about circadian time 2.

13. The method of claim 9 wherein the phase-shifting effect is a phase delay to alleviate jet lag caused by transmeridional travel to the west, and melatonin is administered to the human at about circadian time 0.

14. The method of claim 1 wherein the phase-shifting effect is alleviating winter seasonal affective disorder.

15. The method of claim 14 wherein the phase-shifting effect is a phase advance to alleviate winter seasonal affective disorder, and melatonin is administered to the human at about circadian time 7 to about circadian time 11.

16. The method of claim 14 wherein the phase-shifting effect is a phase advance to alleviate winter seasonal affective disorder, and melatonin is administered to the human at about circadian time 7.5.

17. The method of claim 14 wherein the phase-shifting effect is a phase delay to alleviate winter seasonal affectire disorder, and melatonin is administered to the human at about circadian time 20 to about circadian time 2.

18. The method of claim 14 wherein the phase-shifting effect is a phase delay to alleviate winter seasonal affectire disorder, and melatonin is administered to the human at about circadian time 0.

19. The method of claim 1 wherein the phase-shifting effect is alleviating schedule-related circadian rhythm disorders.

20. The method of claim 19 wherein the phase-shifting effect is a phase advance to alleviate schedule-related disorders caused by an earlier schedule, and melatonin is administered to the human at about circadian time 7 to about circadian time 11.

21. The method of claim 19 wherein the phase-shifting effect is a phase advance to alleviate schedule-related disorders caused by an earlier schedule, and melatonin is administered to the human at about circadian time 7.5.

22. The method of claim 19 wherein the phase-shifting effect is a phase delay to alleviate schedule-related disorders caused by a later schedule, and melatonin is administered to the human at about circadian time 20 to about circadian time 2.

23. The method of claim 19 wherein the phase-shifting effect is a phase delay to alleviate schedule-related disorders caused by a later schedule, and melatonin is administered to the human at about circadian time 0.

24. The method of claim 1 optionally including the step of providing dim light or dark conditions at the time of melatonin administration.

25. The method of claim 24 optionally including the step of providing bright light conditions capable of suppressing endogenous melatonin production in a human at a time when endogenous melatonin is normally produced by an individual human.

26. The method of claim 24 wherein the dim light conditions are provided by having the individual human wear dark goggles.

27. The method of claim 24 wherein the dim light conditions are provided by having the individual human wear goggles with red lenses.

28. The method of claim 1 optionally including the step of providing bright light conditions capable of suppressing endogenous melatonin production in a human at a time when endogenous melatonin is normally produced by an individual human.

29. The method of claim 1 optionally including the step of administering to the human an amount of a pharmaceutical agent, said agent being capable of affecting endogenous melatonin activity, wherein said agent is administered at a time that is about 1 hour prior to the individual human'"'"'s dim light endogenous melatonin onset time.

30. The method of claim 29 wherein the pharmaceutical agent is selected from the group consisting of noradrenergic and serotonergic re-uptake blockers, alpha-2-noradrenergic antagonists, alpha-1-noradrenergic agonists, monoamine oxidase inhibitors, beta-adrenergic blockers, benzodiazepines and metabolic precursors of melatonin selected from the group consisting of tryptophan, 5-hydroxytryptophan, serotonin and N-acetylserotonin.

31. The method of claim 1 comprising the additional step of estimating the human'"'"'s dim light endogenous melatonin onset time as being at a fixed time relative to a human physiological circadian rhythm.

32. The method of claim 1 optionally including the step of administering to the human an amount of a pharmaceutical agent, said agent being capable of stimulating melatonin receptors in the suprachiasmatic nuclei of the hypothalamus or elsewhere in the animal to achieve a phase-shifting effect.

33. The method of claim 1 optionally including the step of administering to the human an amount of a pharmaceutical agent, said agent being capable of stimulating melatonin receptors in the suprachiasmatic nuclei of the hypothalamus or elsewhere in the animal to achieve an effect.

34. The method of claim 1 comprising the additional step of estimating the human'"'"'s dim light endogenous melatonin onset circadian time as being at a time later than CT 14 in a human being having below normal endogenous melatonin production levels.

35. The method of claim 1 optionally including the step of administering to the human an amount of a pharmaceutical agent, said agent being capable of blocking melatonin or melatonin agonist binding to melatonin receptors in a human to achieve a melatonin phase-shifting effect.

36. The method of claim 1 optionally including the step of providing bright light at an intensity of about 500 lux to about 100,000 lux, wherein the bright light complements the phase-shifting effects of exogenous melatonin administration.

37. The method of claim 36 wherein the phase-shifting effect is a phase advance and bright light is provided to the human at about circadian time 18 to about circadian time 2.

38. The method of claim 36 wherein the phase-shifting effect is a phase delay and bright light is provided to the human at about circadian time 12 to about circadian time 18.

39. The method of claim 1 wherein the phase-shifting effect is the adjustment of circadian rhythms into synchrony with the day/night, light/dark cycle in a human having a circadian rhythm-related sleep disorder.

40. The method of claim 39 wherein the sleep disorder is advance sleep phase disorder and melatonin is administered to the human at about circadian time 7 to about circadian time 11.

41. The method of claim 39 wherein the sleep disorder is advance sleep phase disorder and melatonin is administered to the human at about circadian time 7.5.

42. The method of claim 39 wherein the sleep disorder is delayed sleep phase disorder and melatonin is administered to the burman at about circadian time 20 to about circadian time 2.

43. The method of claim 39 wherein the sleep disorder is advance sleep phase disorder and melatonin is administered to the burnan at about circadian time 0.

44. The method of claim 1 wherein the phase-shifting effect is a phase advance and melatonin is administered to the human at about circadian time 3 to about circadian time 18.

45. The method of claim 1 wherein the phase-shifting effect is a phase delay and melatonin is administered to the human at about circadian time 12 to about circadian time 6.